Targeted Oncology

, Volume 12, Issue 1, pp 89–95 | Cite as

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

  • Katerina Kopeckova
  • Tomas Buchler
  • Zbynek Bortlicek
  • Karel Hejduk
  • Renata Chloupkova
  • Bohuslav Melichar
  • Petra Pokorna
  • Jiri Tomasek
  • Zdenek Linke
  • Lubos Petruzelka
  • Igor Kiss
  • Jana Prausova
Original Research Article



To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival.

Patients and Methods

The data of patients treated with regorafenib were extracted from the national CORECT registry. The CORECT registry is a non-interventional post-marketing database, gathering information about patients with CRC and treated with targeted agents. Twenty oncology centres in the Czech Republic contributed to this registry. Collected data included patients’ characteristics, disease history, cancer treatments, response to treatments and safety.


A total of 148 patients treated with regorafenib in clinical practice were analysed. At regorafenib initiation, almost all patients were fully active or slightly restricted in physical activity. Regorafenib was not administered as first-line treatment in any patient. Median progression-free survival was 3.5 months and median overall survival was 9.3 months. One-year survival rate was 44.6 %. Four partial responses were observed and 51 stable diseases. Progression was observed in 66 patients (44.6 %). The main reported adverse events were skin toxicity (5.4 %) and fatigue (2.0 %).


Regorafenib is a well-established treatment for pretreated patients with mCRC, however real-life data are scarce. Our results demonstrated slightly better efficacy of regorafenib and better safety profile in patients with mCRC compared to the randomised trials.


Overall Survival Bevacizumab Sorafenib Cetuximab Metastatic Colorectal Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Fifteen comprehensive oncology centres, approved by the authorities and payers, contributed to the registry.

The authors thank Abir Tadmouri, PhD (ClinSerach) for providing editorial assistance in the preparation of the manuscript.

Compliance with Ethical Standards


The institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno received financial support for the CORRECT registry from Bayer, Amgen Merck and Roche.

Conflict of Interest

Katerina Kopeckova received grants and payment for lectures from Bayer.

Tomas Buchler received grants, consulting fees and support for travel from Bayer.

Zbynek Bortlicek has no conflict of interest to declare.

Karel Hejduk has no conflict of interest to declare.

Renta Chloupkova has no conflicts of interest to declare.

Bohuslav Melichar received consulting fees from Roche, Novartis, Astellas, Bristol-Myers Squibb, MSD, Merck, Pfizer, Janssen, support for travel from Roche, Novartis, Astellas, Bristol-Myers Squibb, provision of writting assistance from Roche, Bristol-Myers Squibb, payment for lectures Roche, Novartis, Astellas, Bristol-Myers Squibb, MSD, Merck, Pfizer, Janssen.

Petra Pokorna has no conflicts of interest to declare.

Jiri Tomasek has no conflicts of interest to declare.

Zdenek Linke has no conflicts of interest to declare.

Lubos Petruzelka has no conflicts of interest to declare.

Igor Kiss has no conflicts of interest to declare.

Jana Prausova has no conflicts of interest to declare.


  1. 1.
    Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii1–9.Google Scholar
  2. 2.
    Schmieder R. Regorafenib (BAY 73-4506): antimetastatic activity in a mouse model of colorectal. Cancer Res 2012;72(8 Suppl):Abstract nr 2337.Google Scholar
  3. 3.
    Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des. 2002;8:2255–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–109.CrossRefPubMedGoogle Scholar
  7. 7.
    Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Slavicek L, Pavlik T, Tomasek J, et al. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry. BMC Gastroenterol. 2014;14:53.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tougeron D, Desseigne F, Etienne PL et al. REBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients previously treated for metastatic colorectal cancer (mCRC). Ann Oncol. 2014;25(suppl_4): iv167–iv209.Google Scholar
  10. 10.
    Van Cutsem E, Ciardiello F, Seitz J-F, et al. LBA-05 Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol. 2015;26(suppl_9):42–70.Google Scholar
  11. 11.
    Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–29.CrossRefPubMedGoogle Scholar
  12. 12.
    Garcia-Alfonso P, Feliu J, Garcia-Carbonero R, et al. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer? Clin Transl Oncol. 2016;1:1.Google Scholar
  13. 13.
    Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338–44.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hofheinz RD, Arnold D, Kubicka S, et al. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. Oncol Res Treat. 2015;38:300–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16:937–48.CrossRefPubMedGoogle Scholar
  16. 16.
    NCCN. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. Version3. 2011.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Katerina Kopeckova
    • 1
  • Tomas Buchler
    • 2
  • Zbynek Bortlicek
    • 3
  • Karel Hejduk
    • 3
  • Renata Chloupkova
    • 3
  • Bohuslav Melichar
    • 4
  • Petra Pokorna
    • 1
  • Jiri Tomasek
    • 5
  • Zdenek Linke
    • 1
  • Lubos Petruzelka
    • 6
  • Igor Kiss
    • 6
  • Jana Prausova
    • 1
  1. 1.Department of Oncology, University Hospital in MotolCharles UniversityPragueCzech Republic
  2. 2.Department of Oncology, First Faculty of Medicine and Thomayer HospitalCharles UniversityPragueCzech Republic
  3. 3.Institute of Biostatistics and Analysis, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  4. 4.Department of OncologyPalacky University Medical and Teaching HospitalOlomoucCzech Republic
  5. 5.Department of Oncology, Department of Comprehensive Cancer CareMasaryk Memorial Cancer InstituteBrnoCzech Republic
  6. 6.Department of OncologyGeneral Faculty Hospital, Charles UniversityPragueCzech Republic

Personalised recommendations